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ABSTRACT
Donor CD8 T cells can be potent mediators of graft-versus-host disease (GVHD) after allogeneic hemato-
poietic cell transplantation to either major histocompatibility complex (MHC) class I–or multiple minor
histocompatibility antigen–mismatched recipients. To develop small molecular inhibitors of CD8 T-cell
activity, theoretical structural analysis of the human CD8 molecule was previously used to identify potential
functional surface epitopes that interact with the MHC class I molecule. The DE loop (p71-78) was identified
as such a target region, and a panel of synthetic cyclized peptide mimics of this region were tested for their
inhibitory effects on cytotoxic T lymphocyte activity in human cell-mediated lympholysis assays. Peptide 1109
(CKRLGDTFVC) was most effective at inhibiting specific target cell lysis. Accordingly, studies were con-
ducted to determine whether there was sufficient cross-species homology in the DE loop region and its
nonpolymorphic interactive site on the 2-microglobulin domain of the MHC class I molecule to allow similar
inhibition of murine CD8 cytotoxic T lymphocyte activity. On the basis of strong in vitro inhibitory activity
of 1109 in the murine system, the capacity of the peptide to inhibit in vivo CD8 T-cell effector functions in
skin and hematopoietic stem cell transplantation models was examined. In the C57BL/6 anti-bm1 skin allograft
rejection model, across an MHC class I barrier, a single injection of 1109 at the time of transplantation
significantly prolonged graft survival. Moreover, 1109 administered at the time of transplantation in the
multiple minor histocompatibility antigen–disparate B10.BR3CBA GVHD model significantly prolonged the
survival of lethally irradiated mice that underwent transplantation with donor bone marrow cells and CD8 T
cells. Histopathologic analysis confirmed that mice treated with the synthetic peptide exhibited diminution of
epithelial target cell injury. Specificity of the peptide effect was evidenced by draining lymph node cells from
B10.BR mice that had been challenged with CBA lymphocytes and simultaneously treated with 1109. These
cells could not generate secondary proliferative responses in vitro upon stimulation with CBA splenocytes but
could respond to third-party C57BL/6 stimulation. Thus, the 1109 peptide has potential application in the
prevention of CD8-mediated GVHD development.
© 2004 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Allogeneic hematopoietic cell transplantation
HCT) is currently used as a treatment for a number of
iseases, including leukemias, myelodysplasia, aplastic
nemia, and severe combined immunodeﬁciency [1].
ajor complications from allogeneic HCT include the a
B&MTevelopment of graft-versus-host disease (GVHD), en-
raftment failure, infections from long-term immunoin-
ompetence, and leukemic relapse. GVHD develops as a
ytokine-driven response of mature donor T cells, which
ontaminate the hematopoietic stem cell inoculum,
gainst major histocompatibility complex (MHC) and/or
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6inor histocompatibility antigens (miHA) expressed by
he allogeneic recipient [2]. The principal target organs
f GVHD include the gastrointestinal tract, liver, skin,
nd lymphoid organs. Although depletion of donor T
ells is an effective means of preventing GVHD, donor
cells are necessary for providing graft-versus-leukemia
ffects, and in their absence, the incidence of leukemic
elapse is high [3,4]. Therefore, a major goal of HCT is
o develop approaches that minimize GVHD risk while
reserving donor T cells that mediate graft-versus-leu-
emia responses.
CD8 cytotoxic T lymphocytes (CTLs) play a
ominant role in the GVHD response across either
HC class I [5] or multiple miHA barriers in exper-
mental transplant models [6,7] and in clinical HCT
8-10]. T-cell receptors (TCRs) on CD8 T cells
ecognize antigenic peptides bound to MHC class I
olecules on the surface of target cells [11], and the
D8 molecule is a co-receptor for this interaction,
rimarily via recognition of nonpolymorphic sites on
he MHC class I 3 domain [12]. CD8 also seems to
e involved in the intracellular signaling that leads to
-cell activation, because of its cytoplasmic associa-
ion with the tyrosine kinase p56lck [13,14]. CD8 is a
ember of the immunoglobulin superfamily [15] and
onsists of an amino-terminal immunoglobulin-vari-
ble domain, an extracellular spacer that carries the
tructural features of the immunoglobulin hingelike
egion, a transmembrane domain, and an intracellular
ytoplasmic tail [16,17]. Because the CD8 chain may
e mediating protein-protein interactions via the im-
unoglobulin-variable domain complementarity-de-
ermining region (CDR)–like regions (similar to that
ound for CD4 [18]), the CD8 molecule is well suited
or the design of peptide mimics. This has been facil-
tated by elucidation of the crystal structure of the
uman CD8 homodimer and cloning of the glyco-
rotein [19,20]. The amino-terminal immunoglobulin-
ariable domain was found to contain 2 antiparallel
-sheets of 4 and 5 strands and 3 CDR-like loops
CDR1, 2, and 3) [20]. Thus, a synthetic peptide
nalog mapping approach was used for the murine
D8 chain to determine the structure/function re-
ationship of active surfaces potentially involved in
lass I binding. A murine CDR2 region peptide mimic
SC4) was identiﬁed that inhibited activity in cell-
ediated lympholysis (CML) assays and prolonged
HC class I–disparate skin allograft survival in vivo
21]. However, this peptide did not affect human
D8 T-cell activity, likely because of several amino
cid differences between the murine and human
DR2 regions.
In addition to the CDR2 loop (Ser-53-Lys-56),
he resolved crystal structure of the human CD8
omodimer revealed a number of surface loops poten-
ially involved in molecular interactions of the CD8
o-receptor with the MHC class I molecule. Such sites i
70nclude the CDR1 loop (Leu-26-Pro-29) and the DE
oop (Leu-73-Thr-76); the latter seems to engage a
onpolymorphic site on the 2-microglobulin domain
hat is an integral component of the class I structure
22]. Therefore, 3 cyclized peptide mimics—the 1108
eptide (CYLSQNPKC), the 1110 peptide (CVLL-
NPTSGC), and the 1109 peptide (CKRLGDT-
VC)—were derived from the human CDR2, CDR1,
nd DE loop regions of the D1 domain, respectively
23]. Initial experiments demonstrated that the 1109
eptide effectively inhibited human allogeneic CTL
ctivity, both at the generation and effector stages
23].
To determine whether such human-derived pep-
ides have a cross-species effect in murine systems
elevant to GVHD pathogenesis, peptides 1108, 1109,
nd 1110 were analyzed for inhibitory effects in mu-
ine CML assays. The DE loop peptide (1109) was the
ost effective in inhibition of speciﬁc target-cell lysis.
valuation of the 1109 peptide in a CD8-dependent
HC class I–disparate murine model of skin allograft
ejection demonstrated signiﬁcant prolongation of
raft survival when administered as a single intrave-
ous injection at the time of transplantation. When
ested in a CD8-mediated model of GVHD directed
o multiple miHA differences (the B10.BR3CBA
train combination [7]), the 1109 peptide effectively
rolonged survival. In addition, the peptide was most
ffective when administered at the time of transplan-
ation, thus suggesting potential interference with the
nitial alloreactive stimulation of donor CD8 T cells.
istopathologic analysis of mice at day 30 after trans-
lantation showed decreased lymphoid inﬁltration and
pithelial injury of GVHD target tissues in animals
reated with the 1109 peptide. Furthermore, T-cell
epertoire analysis by TCR V CDR3-size spectra-
yping supported the notion that alloreactive donor
D8 T cells were not expanding in the recipient
pleen. Taken together, these data suggest that the
uman DE loop peptide mimic may have potential as
treatment to ameliorate the development of CD8-
ediated GVHD.
ATERIALS AND METHODS
nimals
B10.BR (H-2k) and C57BL/6.C-H-2bm1 (bm1)
ice were purchased from The Jackson Laboratories
Bar Harbor, ME). CBA/Ncr (H-2k), SJL/Ncr (H-2s),
nd C57BL/6 (B6; H-2b) mice were purchased from
he National Cancer Institute (Frederick, MD). Male
ice were used as donors at 6 to 12 weeks of age and
s recipients at 9 to 16 weeks of age. All mice were
oused in microisolator cages and handled under ster-
le conditions.
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CD8 Peptide Inhibition of GVHD
Bonoclonal Antibodies
The in vivo depletion of CD8 T cells was per-
ormed by intraperitoneal administration of anti-CD8
onoclonal antibody (mAb; clone 2.43; American
ype Culture Collection [Manassas, VA] TIB-210;
:100 dilution of ascites ﬂuid, 0.2 mL). For T-cell
epletion of the donor bone marrow inoculum, ascites
uid of anti-Thy1.2 (clone J1j, rat immunoglobulin
; American Type Culture Collection TIB-184;
:100 dilution) mAb was used along with guinea pig
omplement (1:20 dilution; Rockland, Boyerton, PA).
D4 T-cell subset depletion was accomplished by
sing ascites ﬂuid of anti-CD4 (RL172; rat immuno-
lobulin M [24]) mAb and guinea pig complement.
henotypic analysis of cells by ﬂow cytometry was
erformed with puriﬁed ﬂuorescein isothiocyanate–
onjugated rat anti-murine CD4 (clone RM4-5) and
D8 (clone 53-6.7) mAbs purchased from Pharmin-
en (San Diego, CA). For in situ immunohistochem-
cal tissue staining, rat anti-murine CD4, CD8, vas-
ular cell adhesion molecule (VCAM; CD106), and
latelet/endothelial cell adhesion molecule (PECAM;
D31) mAbs and rat isotype control, as well as ham-
ter anti-murine intercellular adhesion molecule
ICAM; CD54) mAb and a hamster isotype control,
ere all purchased from Pharmingen.
eptides
The 1109 peptide (CKRLGDTFVC), a scram-
led sequence of the 1109 peptide (1255 scrambled;
RTFKGDLVC), the 1108 peptide (CYLSQN-
KC), and the 1110 peptide (CVLLSNPTSGC) were
ynthesized on an Applied Biosystems 430A (Foster
ity, CA) fully automated peptide synthesizer, as pre-
iously described [22]. Intramolecular disulﬁde bonds
ere enriched by air oxidation and monitored by
igh-performance liquid chromatography analysis un-
il the peptides exhibited more than 95% cyclization.
eptides were then extensively puriﬁed by high-per-
ormance liquid chromatography and stored lyophi-
ized under vacuum pressure at room temperature.
ML Assays
Standard in vitro murine CML assays were used to
est the effects of peptide on CD8 alloreactive T-cell
unction against MHC differences. Lymph node cells
ere isolated from B6 mice and co-cultured with ir-
adiated (20 Gy) splenocytes from SJL (H-2s) mice.
fter 5 days of incubation at 37°C with 7% CO2,
TL activity was measured in a standard 4-hour chro-
ium 51 (51Cr)–release CML assay by using lympho-
last targets derived from concanavalin A (Con A)–
timulated SJL spleen cells at effector-target (E:T) cell
atios of 30, 10, 3, and 1:1.
To test CTL activity against miHA differences,
esponding T cells were isolated from the lymph t
B&MTodes of B10.BR mice presensitized with CBA spleno-
ytes 3 weeks before (1.5 107 cells intraperitoneally)
nd co-cultured with irradiated (20 Gy) splenocytes
rom syngeneic B10.BR, allogeneic CBA, or third-
arty B6 mice. After 6 days of incubation at 37°C with
% CO2, CTL activity was measured in a standard
-hour 51Cr-release CML assay by using lymphoblast
argets derived from Con A–stimulated spleen cells at
:T cell ratios of 30, 10, 3, and 1:1.
The percentage of speciﬁc lysis was determined as
he mean percentage lysis of quadruplicate experimen-
al samples minus the percentage of spontaneous re-
ease (target cells incubated in media alone), divided
y the percentage of maximum release (target cells
ncubated in centrimide saline) minus the percentage
f spontaneous release.
kin Allograft Model
Tail skin grafts from bm1 or SJL mice were pre-
ared and transplanted to B6 mice, according to the
ethod of Bailey and Usama [25]. Within 1 hour of
ransplantation, either peptides (0.5 mg; 0.2-mL vol-
me; intravenously [IV]) or anti-CD8 mAb (2.43; 0.2
L of a 1:100 dilution of ascites; intraperitoneally)
ere administered to allograft recipients. Grafts were
bserved daily for signs of rejection, denoted as such
hen more than 90% of the graft exhibited loss of
air, pigmentation, and the development of scar tis-
ue.
ixed Lymphocyte Reaction (MLR)
Splenocytes from CBA mice were processed for
uspension, irradiated at 20 Gy, and injected (1.5 
07) into the footpads of B10.BR hosts. These mice
lso received IV injections of either phosphate-buff-
red saline or 1109 peptide (0.5 mg/0.2 mL). On day
, draining lymph node cells (inguinal and popliteal)
ere isolated and cultured (2  105) in a 96-well plate
ith 2  105 irradiated (20 Gy) splenocytes from
yngeneic B10.BR, allogeneic CBA, or third-party B6
ice. On days 5 to 7 of culture, 1 Ci of 3H-thymi-
ine per well was added for a 6-hour pulse to measure
roliferation.
ouse Model of GVHD
CBA mice were lethally irradiated (13 Gy, split
ose; 4 hours apart) by exposure from a Gammacell
Gammacell 40; MDS, Nordion, Ontario) cesium 137
ource and injected (IV) with 2  106 B10.BR anti–T
ell–depleted bone marrow (ATBM) cells either alone
r in combination with 3  106 B10.BR CD8 en-
iched T cells. Mice were either left untreated or
reated with the 1109 peptide (0.5 mg/0.2 mL; IV) at
or 24 hours after transplantation. Mice were moni-
ored daily for weight loss and morbidity.
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6istology
Mice from peptide-treated, untreated, and ATBM
10.BR3CBA experimental groups were sampled
n  3) at 29 days after transplantation. Ear skin and
leum were harvested for routine histology and, in
ome cases, for frozen tissue analysis. Apoptotic injury
as evaluated in hematoxylin and eosin–stained tissue
ections by determining the mean apoptotic index
average number of apoptotic epithelial cells per mil-
imeter of skin or per cross-sectional crypt lumen of
ut), as previously described [26]. In addition, a semi-
uantitative grade analysis (0-3) was used to corre-
ate T-cell inﬁltration and apoptosis on the basis of
he following criteria.
For skin, 0  normal; 1  focal, noncontiguous
ymphoid inﬁltration without satellitosis; apoptosis
ithout lymphoid apposition; and focal epidermal
hickening (5 keratinocytes); 2  focal, noncontig-
ous lymphoid inﬁltration with satellitosis; apoptosis
ith lymphoid apposition; and focal epidermal thick-
ning (5 keratinocytes); and 3  conﬂuent interface
ymphoid inﬁltration; apoptosis with satellitosis; and
pidermal thickening (5 keratinocytes).
For gut, 0  normal; 1  focal inﬂammatory
nterstitial expansion of lamina propria; apoptosis
resent in 25% of crypts; and 50% diminution of
aneth cells; 2  focal inﬂammatory interstitial ex-
ansion of lamina propria with crypt exocytosis; apo-
tosis present in 25% to 50% of crypts; occasional
ersistence of Paneth cells (10%); and 3  diffuse
nﬂammatory interstitial expansion of lamina propria;
poptosis present in 50% of crypts; no Paneth cells.
The terminal uridine deoxynucleotidyl transferase
nd ligation (TUNEL) technique was used to detect
poptotic cells in situ [26]. In addition, immunohisto-
hemistry was performed on serial cryosections, each
eparated by 5 m, as previously described [27]. Ap-
ropriate mAb were used to detect murine CD4 and
D8 molecules and VCAM (CD106), PECAM
CD31), and ICAM (CD54).
CR V CDR3-Size Spectratyping
Total cellular RNA was prepared as previously
escribed [28] from splenic T cells of 3 pooled mice
er group and was homogenized in 1 mL of Ultraspec
Biotecx Laboratories, Houston, TX), with recovery
etermined by spectrophotometry. The poly(A) por-
ion of the total RNA was converted into complemen-
ary DNA by using oligo(dT) as a primer for reverse
ranscription. Polymerase chain reaction (PCR) was
erformed by using a ﬂuorescent-labeled constant
rimer (Cb) purchased by PE-Applied Biosystems
nd a V11-speciﬁc primer. The primers used have
een previously described [28]. Thirty-ﬁve cycles of
mpliﬁcation were performed, and upon completion
f PCR, the ﬂuorescently labeled PCR products were s
72un on a sequencing gel and analyzed by Genotyper
enescan software (PE-Applied Biosystems). V fam-
ly histogram peaks were numbered 1 to 7 from the
horter to the longer product sizes within the spectra-
ype.
tatistical Analysis
To determine the signiﬁcance of the spectratype
ata for the V11 family, spectratype analysis was
epeated 3 times for normal B10.BR control CD8
plenic T cells and twice for the experimental groups.
he areas under the corresponding peaks were aver-
ged for each V histogram. A peak was considered to
e skewed if the mean area under the peak was greater
han the mean plus 3 times the SD of the correspond-
ng normal control peak [29]. For both skin allograft
ejection and GVHD, mid survival times (MSTs) were
alculated as the extrapolated 50% survival point of a
inear regression through all of the rejection or death
ata points, respectively, including 0. Statistical com-
arisons of survival data between experimental groups
ere based on individual days of rejection or death
nd were performed by the nonparametric Wilcoxon
igned rank test.
ESULTS
ffect of CD8 DE Loop Peptide Analogs in Murine
ML
To establish the efﬁcacy of DE loop peptide mim-
cs derived from human CD8 in a murine system, 3
eptides (1108-1110) were tested for their inhibitory
ffects in murine CML assays by their addition at the
ffector phase (Figure 1). At an E:T ratio of 30:1, 1109
ost effectively inhibited (60%-70%; P .05) speciﬁc
ysis of target cells and was not signiﬁcantly different
rom treatment with anti-CD8 mAb in the culture.
he 1108 CDR2-derived peptide exhibited approxi-
ately 50% inhibition (P  .05), whereas the 1110
DR1-derived peptide did not signiﬁcantly inhibit
peciﬁc lysis as compared with the untreated control
roup. Thus, the 1109 DE loop peptide was selected
or further efﬁcacy analysis in murine models.
ffect of the 1109 Peptide in a Skin Allograft
ejection Model
To examine the in vivo effect of 1109, the CD8-
ediated B6 anti-bm1 MHC class I–disparate skin
ransplantation model was initially evaluated. In this
odel, phosphate-buffered saline–treated mice had a
raft MST of 12.2 days (Figure 2), whereas mice
reated with a single injection of anti-CD8 mAb dis-
layed prolonged graft survival (MST of 39.7 days);
0% of the mice never rejected their allograft. Treat-
ent with 1109 within 1 hour of transplantation also
igniﬁcantly improved the MST to 32 days (P  .01),
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rejection and an MST of 12.9 days (P  .07). The data are pooled from 2
CD8 Peptide Inhibition of GVHD
BB&MTith 25% long-term survival. In contrast, the 1255-
crambled control peptide had no effect on prolonged
llograft survival, with complete rejection and an
ST of 12.9 days (P  .07).
ffect of 1109 in a GVHD Model
The B10.BR3CBA multiple miHA-mismatched
VHD model was selected for testing the in vivo
fﬁcacy of the 1109 peptide because disease in this
ase depends on donor CD8 T-cell alloreactivity [7].
BA mice were exposed to lethal irradiation (13 Gy;
plit dose) and infused with B10.BR ATBM cells (2 
06) alone or in combination with a highly enriched
opulation of B10.BR CD8 T cells (3  106). The
109 peptide was then administered to appropriate
BA recipient mice (IV; 0.5 mg; 0.25 mL) either
ithin the ﬁrst hour or at 24 hours after transplanta-
ion. Mice infused with donor ATBM cells alone
hrived well after transplantation, and 80% exhibited
ong-term survival to day 90 (Figure 3). In contrast,
ymptoms of GVHD (cachexia, diarrhea, and alope-
ia) developed in mice infused with donor ATBM and
D8 T cells. All recipients died by day 38, with an
ST of 26.1 days. Treatment of recipient mice with
he 1109 peptide within the ﬁrst hour of transplanta-
ion resulted in 76.2% long-term survival (P  .23
ompared with ATBM alone; P .001 compared with
VHD control without 1109), with minimal clinical
igns of GVHD. Mice treated with 1109 at 24 hours
fter transplantation also had signiﬁcantly prolonged
urvival compared with untreated CD8 T-cell recip-
ents (P  .02), although all mice in this group still
n a CD8-dependent MHC class I–disparate model. Tail skin grafts
r of transplantation, either peptides (0.5 mg; 0.2-mL volume; IV)
ally) were administered to allograft recipients. Phosphate-buffered
ith a single injection of anti-CD8 mAb displayed prolonged graft
eatment with 1109 also signiﬁcantly improved the MST to 32 days
control peptide had no effect on allograft survival, with completeigure 1. Effect of DE loop peptide analogs on a murine CML
esponse. The efﬁcacy of 3 DE loop peptides (1108-1110) derived
rom human CD8 were tested for their inhibitory effects in a
tandard murine CML assay. Lymph node cells were isolated from
6 (H-2b) mice and cocultured with irradiated (20 Gy) splenocytes
rom SJL (H-2s) mice. After 5 days of incubation, CTL activity was
easured in a standard 4-hour 51Cr-release CML assay by using
ymphoblast targets derived from Con A–stimulated SJL spleen
ells. At a E:T ratio of 30:1, 1109 was found to have the most
nhibition (60%-70%; P  .05) of the speciﬁc lysis of target cells,
nd this was not signiﬁcantly different from treatment with anti-
D8 mAb in the culture. The 1108 CDR2-derived peptide exhib-
ted almost 50% inhibition (P  .05), whereas the 1110 CDR1-
erived peptide had no signiﬁcant inhibition of speciﬁc lysis as
ompared with the untreated control. The data are from a single
epresentative experiment.igure 2. Human CD8 DE loop peptide 1109 prolongs skin graft survival i
rom bm1 mice were prepared and transplanted to B6 mice. Within 1 hou
r anti-CD8 mAb (2.43; 0.2 mL of a 1:100 dilution of ascites; intraperitone
aline–treated mice had a graft MST of 12.2 days, whereas mice treated w
urvival (MST of 39.7 days); 40% of the mice never lost their allograft. Tr
P  .01), with 25% long-term survival. In contrast, the 1255-scrambledsimilar experiments.
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6ied of GVHD by day 50 (MST of 38.7 days). Thus,
109 was most effective at inhibiting GVHD when
dministered at earlier stages of donor CD8 T-cell
ntihost alloreactivity.
istologic Analysis in the GVHD Model
Recipient mice were sampled at day 29 after trans-
lantation for histopathologic assessment of the skin
nd intestinal tract. CBA recipients of B10.BR ATBM
nd CD8 T cells exhibited marked lymphocyte in-
ltration and apoptotic injury in the skin (Figure 4A)
nd intestinal crypts (Figure 4B) compared with
TBM-negative control groups (Figure 4E and F). In
ontrast, mice treated with the 1109 peptide within 1
our of donor cell transplantation exhibited dimin-
shed epithelial injury in both target organs (Figure
C and D). Semiquantitative grading of epithelial in-
ury in both skin and gut tissues conﬁrmed that 1109
reatment signiﬁcantly reduced GVHD-related pa-
hology (Figure 5A), although some injury was still
vident in the skin in 1109-treated animals in com-
arison to the ATBM control mice. The efﬁcacy of
109 treatment was further supported by quantitation
f apoptotic target cells (Figure 5B) and conﬁrmatory
UNEL staining (Figure 6). However, analysis of
D8 T-cell homing patterns and cytokine-induced
dhesion molecule expression (ICAM-1 and VCAM-1)
n the skin revealed an equivalent expression in both
eptide-treated and -untreated animals (Figure 7).
igure 3. Effect of 1109 on the development of GVHD. CBA m
V with B10.BR ATBM cells (2  106) alone or in combination
ecipients were then either left untreated or treated with the 11
ice infused with donor ATBM cells alone exhibited 80% long-t
ice infused with donor ATBM and CD8 T cells all succumbed
ith the 1109 peptide within the ﬁrst hour of transplantation res
ith ATBM alone; P  .23), with minimal clinical symptoms of
igniﬁcantly prolonged survival compared with untreated CD8 T
y day 50 (MST of 38.7 days). The data are pooled from 3 similar
rom 1 of the experiments.
74hus, the 1109 peptide seemed to have selectively
nhibited the allostimulatory stage of GVHD initia-
ion and subsequent CD8T cell–mediated target cell
njury, without abrogation of cytokine-induced adhe-
ion and homing interactions.
ffect of the 1109 Peptide on TCR CDR3-Size Use
f a Responding V Family in the GVHD Model
To verify the inhibitory effect of 1109 on the
ctivation and subsequent expansion of alloreactive T
ells, we used PCR-based TCR CDR3-size spectra-
ype analysis to identify the T-cell responses gener-
ted during the onset and development of GVHD, as
reviously described [28,29]. Whereas the spectratype
istogram proﬁle of a nonreactive T-cell V family
opulation exhibits a Gaussian distribution of CDR3-
ize peaks, clonal or oligoclonal expansions of allo-
eactive T cells within a given V family are identiﬁed
y signiﬁcantly increased intensity of 1 or more his-
ogram peaks. Spectratype analysis of splenic T cells
arvested from lethally irradiated CBA recipients of
.5  107 B10.BR CD8 T cells 10 days after trans-
lantation exhibited signiﬁcant CDR3-size skewing of
he V11 family (Figure 8). In contrast, splenocytes
rom similarly transplanted CBA mice also treated
ithin the ﬁrst hour with 1109 peptide (0.5 mg; IV;
.2 mL) failed to exhibit expansion in the V11 family
Figure 8). This result was consistent with inhibition
f CD8 donor antihost alloreactive expansion.
re exposed to lethal irradiation (13 Gy; split dose) and injected
highly enriched population of B10.BR CD8 T cells (3  106).
tide (0.5 mg/0.2 mL; IV) at 0 or 24 hours after transplantation.
vival, with termination of the experiments at day 90. In contrast,
HD by day 38 (MST of 26.1 days). Treatment of recipient mice
n 76.2% long-term survival (no signiﬁcant difference compared
. Mice treated with 1109 at 24 hours after transplantation had
ecipients (P  .02), but all mice in this group still died of GVHD
ments, except for data for the 1109 (24-hour) group, which cameice we
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Bn Vitro Proliferative Capacity after In Vivo 1109
reatment
To determine the speciﬁcity of action of the 1109
eptide for CD8 T cells interacting with their cog-
ate antigens, residual in vitro proliferative responses
o allostimulation after in vivo peptide treatment were

igure 4. Twenty-nine days after transplantation, animals transpla
istopathologic changes associated with GVHD. The skin displayed
atellitosis. In the gut, inﬂammatory interstitial expansion of the la
f Paneth cells were observed. Animals transplanted with CD8 T c
ecrease in tissue injury (C, skin; D, gut). The skin showed only
oreover, the gut displayed only focal apoptosis and inﬂammatory
igniﬁcant histopathologic changes were not observed in the ATBM
roup, and representative sections are displayed.valuated. CD8 T cells were prepared from the
B&MTraining lymph nodes (inguinal and popliteal) of
10.BR mice 3 days after subcutaneous intrafootpad
hallenge with 2  107 irradiated CBA splenocytes
nd either treated or not with the 1109 peptide. Mixed
ymphocyte reaction cultures were initiated by co-
ncubating the T cells with irradiated syngeneic
B10.BR), allogeneic (CBA), and third-party (B6)
nly with CD8 T cells (A, skin; B, gut) demonstrated signiﬁcant
al thickening, prominent lymphoid inﬁltration, and apoptosis with
ropria with associated lymphoid cryptitis, crypt apoptosis, and loss
then treated with 1109 peptide demonstrated a marked qualitative
ymphoid inﬁltration and apoptosis without lymphoid apposition.
sion of the lamina propria and a mild diminution of Paneth cells.
rol animals (E, skin; F, gut). Three mice were analyzed from eachnted o
epiderm
mina p
ells and
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6plenocytes. Throughout days 5 to 7 of culture, the
nti-CBA response was signiﬁcantly inhibited in the
roup from 1109-treated mice as compared with the
ntreated group and was not signiﬁcantly greater than
he syngeneic control response (Figure 9). In contrast,
hird-party allostimulation resulted in equivalent and
ven slightly greater proliferation in the group from
109-treated mice. Thus, the inhibitory effect of 1109
as speciﬁc for the alloreactive response to which it
as exposed in vivo, and it did not affect subsequent
hird-party antigenic stimulation.
igure 5. Animals treated with the CD8 peptide inhibitor demonst
A) mean semiquantitative grade (0 to 3 scale correlating T-cell inﬁ
pithelial cells per millimeter of skin and per cross-sectional ileal c
igure 6. TUNEL staining of apoptotic skin (A and B) and gut (C
fter HCT. TUNEL-positive epidermal cells are denoted by arro
ffected cells. Note the marked diminution in TUNEL-positive cel
ith untreated animals (A and C). The tissues displayed are representative
76ISCUSSION
The putative role of the CD8 co-receptor mole-
ule in T-cell activation makes it an attractive target
or small molecular inhibitors that either destabilize
CR/antigen/MHC-I interaction or alter signal
ransduction to obviate T-cell functioning. Several
xtracellular domains on the CD8 co-receptor protein
rovide potential sites for the use of small peptidean-
agonists. In this study, we demonstrated that the 1109
eptide mimic of the human CD8 DE loop domain
arked diminution of skin and gut epithelial injury as evaluated by
and apoptosis) and (B) mean apoptotic index (number of apoptotic
amples from 3 mice per group were analyzed.
epithelial cells in peptide-treated and untreated animals at 29 days
are visible in intestinal crypts as brown-staining regions within
in and gut of 1109 peptide–treated animals (B and D) as comparedrated m
ltration
rypt). Sand D)
ws and
ls in sksamples from 3 mice per group.
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Bas cross-species efﬁcacy in murine systems and can
nhibit both CTL lytic activity in vitro and the devel-
pment of GVHD in vivo. These activities in murine
odels not only are of practical importance in pro-
iding a means to evaluate peptide efﬁcacy for exper-
mental disease intervention, but also indicate poten-
ial for application in human clinical settings. Indeed,
ecent studies indicate that the murine MHC-I/CD8
nteraction is 4 times stronger than the equivalent
uman interaction [30,31] and, thus, would theoreti-
ally be more difﬁcult to block with the 1109 peptide.
The CD8 molecule plays an important role in the
ctivation of naive CD8 T cells in the presence of
igure 7. Immunohistochemical analysis of selected skin samples a
ithin the superﬁcial dermal and epidermal layers, and focal epiderm
nd untreated recipients. The tissues displayed are representative s
igure 8. CDR3-size spectratype histogram proﬁles of the V11
amily. Reverse transcription-PCR products generated from con-
rol, naive B10.BR splenic CD8 T cells were compared with the
roducts generated from B10.BR anti-CBA untreated (GVHD) and
109-treated CD8 T cells. Signiﬁcant (P  .05) CDR3-size skew-
ng of the ﬁfth peak (arrow) was observed in the untreated GVHD
roducts; this is indicative of alloreactive expansion. The histogram
roﬁle of products from 1109-treated recipients exhibited a Gauss-
an distribution similar to that of the control, suggesting inhibition
 tf the alloreactive B10.BR anti-CD8 T cells.
B&MTpeciﬁc MHC class I–restricted antigens. From a
echanistic point of view, the human CD8 DE loop
Lys-71-Val-78) seems to interact with a nonpolymor-
hic site on the DE loop of the 2-microglobulin
omain of MHC-I molecules, on the basis of the
olved crystal structures [22]. In particular, Asp-75 of
he CD8 DE loop forms a hydrogen bond with Lys-58
f MHC class I. This interaction is one of several
ontact points between the 2 molecules. Interference
ith the DE loop contact point thus could lead to a
eakened overall avidity of the MHC-I/CD8 interac-
ion, in so doing destabilizing TCR recognition of
ntigen/MHC-I or resulting in altered signal trans-
uction during T-cell activation.
The dependency of TCR/antigen/MHC-I inter-
ctions on simultaneous CD8/MHC-I engagement is
ontroversial. Several studies have focused on the ca-
acity of anti-CD8 antibodies to interfere with TCR
ngagement of MHC-I multimers, ﬁnding CD8 to be
ritical for optimum TCR binding capacity [32-34].
owever, surface plasmon resonance data have sug-
ested that TCR/MHC-I interactions are indepen-
ent of CD8/MHC-I engagement [35,36], a concept
lso supported by an anti-CD8 antibody study [30].
hus, the relative importance of CD8/MHC-I inter-
ctions may relate more to the function of CD8-
ssociated lck signaling or its role in the activation
ascade. In this regard, soluble CD8 receptors, de-
pite an extremely low afﬁnity for MHC-I, inhibit
ctivation of CTL by obstructing CD3 	-chain phos-
horylation [37]. In addition, truncated CD8 mole-
ules, lacking a cytoplasmic tail and therefore a p56-
ck association, result in impaired T-cell activation
38]. These and other observations provide evidence
hat although CD8 function is exquisitely sensitive to
isruption, this sensitivity is primarily at the level of
ignal transduction. Thus, the effect of the 1109 pep-
ide may involve, in addition to steric hindrance of the
D8 DE loop/2-microglobulin/MHC-I interac-
9 for CD8 T-cell homing molecules. CD8 T cells are present
ession of ICAM-1 and VCAM-1 are present in both peptide-treated
from 3 mice per group.t day 2
al expr
amplesion and decreased TCR engagement with antigen/
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6HC-I, the production of aberrant signaling that can
nergize or neutralize the CTL in a more permanent
anner. Indeed, peptide efﬁcacy due to steric hin-
rance would be anticipated to produce only a tem-
orary delay in activation of alloreactive donor T cells
n vivo and perhaps a slight prolongation of GVHD
evelopment, considering that the half-life of similar-
ized cyclized peptides in the serum of recipients is
pproximately 20 minutes [39]. Yet, when adminis-
ered solely at the time of donor marrow and T-cell
ransplantation, 1109 peptide treatment results in a
igh incidence of long-term survival with minimal
igns of GVHD (Figure 3). The mechanism of the
109 effect thus is likely to involve more permanent
lteration of incoming alloreactive T cells. Moreover,
he window of opportunity by which to affect the
D8 T-cell response is limited, because administra-
ion at 24 hours after transplantation less effectively
nhibited the development of GVHD (Figure 3). This
bservation would be consistent with a peptide effect
n CD8 signaling and activation, whereby once the T
ell passes a certain point in the transduction process,
he peptide-induced alteration in signals has little ef-
ect. Because within the ﬁrst 24 hours most donor T
ells may have passed the transduction stage, the pep-
ide effect at the end of this interval is likely to inﬂu-
nce a smaller population of T cells, thus resulting in
nly a partial diminution in GVHD immunopathol-
igure 9. Effect of 1109 on in vitro mixed lymphocyte reactions. CD
nd popliteal) of 5 B10.BR mice 3 days after subcutaneous intrafoot
reated or not with the 1109 at 0 or 24 hours. Mixed lymphocyte r
05 irradiated syngeneic (B10.BR), allogeneic (CBA), and third-par
H-thymidine per well was added for a 6-hour pulse to measure pro
rom 1109-treated mice as compared with the untreated group an
esponse. In contrast, third-party allostimulation resulted in equivagy. h
78From the results obtained in the mixed lympho-
yte reaction analysis of CD8 T-cell responses after
n vivo treatment with the 1109 peptide (Figure 9), it
s concluded that only antigen-speciﬁc responses are
ffected—third-party alloantigen reactivity is still fully
otent. Accordingly, in the marrow transplant setting,
he donor CD8 compartment would still maintain an
ntact repertoire and could thus potentially counteract
pportunistic infections and leukemic relapse. Exper-
ments have been planned to test those possibilities in
he miHA murine model.
Epithelial cells are primary targets of injury for the
evelopment of GVHD in the skin and gut of HCT
ecipients. In murine models in which disease results
rom miHA differences, a signiﬁcantly increased level
f keratinocyte apoptosis is observed with the arrival
f effector CD8 T cells in target tissue [26,40]. In
his study, the prolongation of survival of murine
ecipients of miHA-mismatched marrow and CD8
-cell transplants by treatment with the 1109 peptide
as associated with marked amelioration of GVHD
athology in both the skin and gut, as assessed by
emiquantitative grading, quantitation of apoptotic
arget cells, and conﬁrmatory TUNEL staining (Fig-
res 4-6). Nevertheless, CD8 T-cell homing pat-
erns and cytokine-induced adhesion molecule expres-
ion persisted in both peptide-treated and untreated
nimals (Figure 7). Thus, the 1109 peptide seems to

ells were prepared from the pooled draining lymph nodes (inguinal
allenge with 1.5  107 irradiated CBA splenocytes and were either
cultures were initiated by co-incubating 2  105 T cells with 2 
splenocytes in a 96-well plate. On days 5 to 7 of culture, 1 Ci of
n. The anti-CBA response was signiﬁcantly inhibited in the group
not signiﬁcantly greater than the anti-B10.BR syngeneic control
oliferation in the 1109-treated group.8 T c
pad ch
eaction
ty (B6)
liferatio
d wasave selectively inhibited the capacity of donor CD8
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Bcells to mediate target tissue injury, without abro-
ation of cytokine-induced adhesive and homing in-
eractions. Further studies are therefore indicated to
etermine the functional status of inﬁltrating CD8T
ells (ie, cytokine production and cytolytic capacity)
nd whether they can be characterized as members of
he donor antihost alloreactive V T-cell repertoire.
The continued presence of alloreactive CD8 T
ells in target tissue would suggest that a state of
nergy was induced by the 1109 peptide treatment
hat inhibited their expansion (Figure 8) and incapac-
tated their cytotoxic activity, while still allowing par-
ial activation. Perhaps, in an manner analogous to
hat observed in some studies with partial antigen
gonists for CD8 T-cell stimulation [41,42], 1109
xposure may result in production of some inﬂamma-
ory cytokines—in particular, interferon-
. It is well
stablished that interferon-
, among its multiple func-
ions in the development of a T-cell response, can
pregulate adhesion molecule expression [43-45]. The
ole of interferon-
 in cutaneous trafﬁcking of T cells
as also been well documented [46]. Thus, it is plau-
ible that 1109 treatment during allostimulation may
esult in partial activation of CD8 T cells and the
elease of interferon-
, permitting upregulation of
dhesion molecules and the facilitation of tissue inﬁl-
ration, despite the loss of other functional capabili-
ies. In this regard, the induction of CD8 T-cell
ytotoxic anergy with concomitant interferon-
 pro-
uction has also been observed after low-dose supe-
antigen administration in vivo [47].
In conclusion, the capacity of the 1109 DE loop
eptide to inhibit the development of CD8-mediated
VHD in the miHA-mismatched murine model
aises the possibility that such an approach may be
ranslatable to the clinical HCT setting. Further stud-
es of the mechanism of inhibition would aid in the
nderstanding of this novel inhibitor and facilitate
uture clinical trials for HLA class I–disparate HCT
ecipients.
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